Clin Hematol Int. 2024 Jan 12;6(1):13-15. doi: 10.46989/001c.92050. eCollection 2024.
NO ABSTRACT
PMID:38817705 | PMC:PMC11084537 | DOI:10.46989/001c.92050
Recent Content
- Outcomes of relapse after teclistamab therapy in multiple myeloma
- Canada agency backs coverage of new ovarian cancer drug
- (no title)
- Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
- Therapy wins rare pediatric disease designation for hard-to-treat glioma
- November shines a spotlight on pancreatic cancer awareness
- Cero seeking more safety, dosing data on T-cell therapy for AML
- (no title)
- Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma